Neutropenia - Drug Pipeline Landscape, 2023

Neutropenia - Drug Pipeline Landscape, 2023

Neutropenia is a meagre count of neutrophils, a type of white blood cell that helps fight back infections, particularly those caused by bacteria and fungi. There are four types of neutropenia congenital neutropenia, cyclic neutropenia, autoimmune neutropenia, and Idiopathic neutropenia.

Neutropenia symptoms can range from mild to severe-inferior the level of neutrophils, the more intense the symptoms. Typical symptoms include fever, pneumonia, sinus infections, otitis media, gingivitis, navel infection, and skin abscesses.

Neutropenia can be caused by chemotherapy, radiation therapy, and the use of certain drugs and other causes like HIV, hepatitis, tuberculosis, sepsis, and Lyme disease.

Doctors diagnose neutropenia by a simple blood test called a complete blood count (CBC) and bone marrow biopsy.

Neutropenia is treated by granulocyte colony-stimulating factor and Antibiotics.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Neutropenia treatment such as X4P-001, EMD-101, INF904 and others. Key players involved in the development of therapies to treat Neutropenia are CSPC ZhongQi Pharmaceutical Technology Co Ltd, InflaRx NV, Statera Biopharma Inc, Toko Pharmaceutical Industries Co Ltd, X4 Pharmaceuticals and others. One drug is under clinical-stage Phase II clinical trials and one drug are in Phase I clinical trials and some other drugs are under preclinical and discovery stages of development.

In December 2022, X4 Pharmaceuticals presented positive data from Mavorixafor Phase 1b clinical trial in people with chronic idiopathic, cyclic, or congenital neutropenia.

Report Highlights

Global Insight Service's, Neutropenia - Drug Pipeline Landscape, 2023 report provides an overview of the Neutropenia pipeline drugs. This report covers detailed insights on Neutropenia drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Neutropenia pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.